B+
Bull case
20%
Probability
Target price
$55.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
VKTX
Viking TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case depends on successful maintenance-dosing data, continued VANQUISH execution, and oral VK2735 Phase 3 initiation. Full enrollment and multiple obesity formulations support meaningful pipeline optionality.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.5.
What can break
Cash declined to $502 million while losses and R&D spending increased, creating financing and dilution risk. [#SEC-8K-2026-07-29] [#PR-EARNINGS-2026-07-30]
Momentum
19
Value
41
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.00 · Bull $55.00 · Bear $20.00Analysis 2026-08-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $93.11
Why
Momentum19 · Δ7d -11.6
Value41 · Δ7d -0.0
Sentiment64 · Δ7d +5.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +5.5.
Contradictions & invalidation
- • Cash declined to $502 million while losses and R&D spending increased, creating financing and dilution risk. [#SEC-8K-2026-07-29] [#PR-EARNINGS-2026-07-30]
- • Clinical efficacy, tolerability, or durability results for VK2735 may disappoint or be delayed.
- • The bear case is driven by widening losses, substantial clinical spending, declining cash, and binary efficacy or safety risk.
Catalyst clock
2026-08-31
Q2 EPS beat but losses widened and cash declined
Lead driver: Sentiment · See AI snapshot
Momentum
19
9% active weight
Current posture
7d trendSoftening
Δ7d
-11.6
Δ21d
-1.5
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
64
62% active weight
Current posture
7d trendImproving
Δ7d
+5.5
Δ21d
+10.8
Why this grade
Composite grade D. Momentum 19.2 / Value 41.2 / Sentiment 63.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-03. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-08-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$3.92B
Beta
0.76
Shares Out
116.65M
P/E (TTM) · Derived
-10.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.22
Rev YoY
-
EPS YoY
+88.3%
Gross Margin
-
Op Margin
-
Net Debt
-$705.6M
Current Ratio
4.72
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data